Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH002 in Advanced Solid Tumors
NCT06231277Phase 1Completed
- Sponsor
- Zhuhai Beihai Biotech
- Start
- Apr 2022
- Primary completion
- Mar 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabazitaxel in solid tumor, sponsored by Zhuhai Beihai Biotech. Primary endpoints: Tolerability of BH002 at 21 days and Pharmacokinetic characteristics at 216 hours. Started Apr 2022; status: completed.
02
Drugs
cabazitaxel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06231277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231277.